NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 17,045 shares of the Company’s common stock to two new employees (the “Inducement Grants”) on June 1, 2026 (the “Grant Date”). The Inducemen